1 The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The boston area anticoagulation trial for atrial fibrillation investigators. N Engl J Med. 1990;323:1505–11.
2 Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Eaft (european atrial fibrillation trial) study group. Lancet. 1993;342:1255–62.
3 Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: Traditional and bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA neurology. 2013;70:1486–90.
4 Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383:955–62.
5 Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. Xantus: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European heart journal. 2015.
6 Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in «real-world» patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264–73.
7 Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-k antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: A systematic review and meta-analysis. Stroke. 2017.
8 Jauch EC, Saver JL, Adams HP, Jr., Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2013;44:870–947.
9 Yoon CH, Park YK, Kim SJ, Lee MJ, Ryoo S, Kim GM, et al. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: Comparison between patients with versus without stroke. Stroke. 2014.
10 Seiffge DJ TC, Hert L, Gensicke H, Peters N, De Marchis GM, Mayer D, Von Hessling A, Tsakiris D, Lyrer P, Engelter S, Bonati L. Die neuen antikoagulantien bei hirnschlagpatienten - the swiss registry of new anticoagulants in stroke patients (noacisp): A national audit and prospective registry. Schweiz Med Forum 2014;14(50):957–9.
11 Seiffge DJ, Hooff RJ, Nolte CH, Bejot Y, Turc G, Ikenberg B, et al. Recanalization therapies in acute ischemic stroke patients: Impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation. 2015;132:1261–9.
12 Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The european cooperative acute stroke study (ecass). JAMA : the journal of the American Medical Association. 1995;274:1017–25.
13 Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-pa stroke study group. N Engl J Med. 1995;333:1581–87.
14 Xian Y, Federspiel JJ, Hernandez AF, Laskowitz DT, Schwamm LH, Bhatt DL, et al. Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non-vitamin k antagonist oral anticoagulants before stroke. Circulation. 2017;135:1024–35.
15 Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (doacs), apixaban, dabigatran and rivaroxaban. Clinical research in cardiology: official journal of the German Cardiac Society. 2013;102:399–412.
16 Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010;41:1450–8.
17 Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated european heart rhythm association practical guide on the use of non-vitamin-k antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European heart journal. 2017;38:2137–49.
18 Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: Part 2. European heart journal. 2016.
19 Seiffge DJ, Traenka C, Polymeris A, Hert L, Peters N, Lyrer P, et al. Early start of doac after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology. 2016.
20 Cuker A. Laboratory measurement of the non-vitamin k antagonist oral anticoagulants: Selecting the optimal assay based on drug, assay availability, and clinical indication. Journal of thrombosis and thrombolysis. 2016;41:241–7.
21 Seiffge DJ, Traenka C, Polymeris A, Hert L, Fisch U, Peters N, et al. Feasibility of rapid measurement of rivaroxaban plasma levels in patients with acute stroke. Journal of thrombosis and thrombolysis. 2017;43:112–6.
22 Seiffge DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, et al. Intravenous thrombolysis in patients with stroke taking rivaroxaban using drug specific plasma levels – experience with a standard operation procedure in clinical practice. J Stroke. 2017.
23 Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431–41.
24 Connolly SJ, Milling TJ, Jr., Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor xa inhibitors. N Engl J Med. 2016.
25 Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in germany - a national case collection. Int J Stroke. 2017;12:383–91.
26 Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke. 2014;9:627–32.